title: Assessing adaptation of the cancer kinome in response to targeted therapies.
abstract: Cancer cells are dependent on protein kinase signalling networks to drive proliferation and to promote survival, and, accordingly, kinases continue to represent a major target class for development of anti-cancer therapeutics. Kinase inhibitors nevertheless have yielded only limited success with many different malignancies due to the inability of single agents to sustain a durable clinical response. Cancer cell kinomes are highly resilient and able to bypass targeted kinase inhibition, leading to tumour resistance. A novel platform has been developed to analyse the activity of the expressed kinome using MIBs (multiplexed inhibitor beads), which consist of Sepharose beads with covalently immobilized inhibitors that preferentially bind activated kinases. Coupling MIB capture with MS (MIB-MS) allows simultaneous determination of the activity of over 75% of the expressed kinome, facilitating high-throughput assessment of adaptive kinase responses resulting from deregulated feedback and feedforward regulatory mechanisms. The adaptive response frequently involves transcriptional up-regulation of specific kinases that allow bypass of the targeted kinase. Understanding how the kinome reprogrammes to targeted kinase inhibition will allow novel therapeutic strategies to be developed for durable clinical responses.
authors.affiliation: *Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, U.S.A.
authors.forename: Jon S
authors.initials: JS
authors.lastname: Zawistowski
authors.affiliation: *Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, U.S.A.
authors.forename: Lee M
authors.initials: LM
authors.lastname: Graves
authors.affiliation: *Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, U.S.A.
authors.forename: Gary L
authors.initials: GL
authors.lastname: Johnson
mesh_terms: D006801:Humans; D013058:Mass Spectrometry; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D040901:Proteomics
chemical_list: D047428:Protein Kinase Inhibitors
references.citation: Cell Rep. 2013 Sep 26;4(6):1090-9
references.pmid: 24055054
references.citation: Eur J Haematol. 2007 May;78(5):417-31
references.pmid: 17432977
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Mol Cell Biol. 2000 Sep;20(18):6768-78
references.pmid: 10958674
references.citation: Blood. 2008 Apr 1;111(7):3821-9
references.pmid: 18235045
references.citation: Biochemistry. 2011 Sep 20;50(37):7964-76
references.pmid: 21793567
references.citation: Nat Cell Biol. 2004 Apr;6(4):308-18
references.pmid: 15048125
references.citation: Oncotarget. 2013 Jan;4(1):9-17
references.pmid: 23327903
references.citation: Oncol Rep. 2011 Jun;25(6):1517-24
references.pmid: 21424128
references.citation: Cancer Res. 2005 Aug 15;65(16):7096-101
references.pmid: 16103058
references.citation: Nat Chem Biol. 2010 Mar;6(3):166-169
references.pmid: 20154661
references.citation: Nat Chem Biol. 2013 Jan;9(1):3-6
references.pmid: 23238671
references.citation: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references.pmid: 18852116
references.citation: Science. 2001 Aug 3;293(5531):876-80
references.pmid: 11423618
references.citation: Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40
references.pmid: 7972041
references.citation: PLoS One. 2013 Jun 24;8(6):e66755
references.pmid: 23826126
references.citation: Oncologist. 2011;16 Suppl 1:61-70
references.pmid: 21278442
references.citation: Mol Cell Biol. 2004 Mar;24(6):2308-17
references.pmid: 14993270
references.citation: Cancer Cell. 2010 Dec 14;18(6):683-95
references.pmid: 21156289
references.citation: Science. 2007 May 18;316(5827):1039-43
references.pmid: 17463250
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: Nat Commun. 2012 Mar 06;3:724
references.pmid: 22395615
references.citation: PeerJ. 2013 Aug 08;1:e126
references.pmid: 23940838
references.citation: Genes Dev. 2000 Oct 1;14(19):2501-14
references.pmid: 11018017
references.citation: Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
references.pmid: 15897464
references.citation: Cell. 2012 Apr 13;149(2):307-21
references.pmid: 22500798
references.citation: Cancer Cell. 2011 Jan 18;19(1):58-71
references.pmid: 21215704
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):989-1000
references.pmid: 21245089